Copyright
©The Author(s) 2019.
World J Meta-Anal. Jun 30, 2019; 7(6): 323-338
Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.323
Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.323
Subgroup/sensitivity analysis | No. of groups | SMD (95%CI) | P-value | Heterogeneity (I2, P-value) | |
BMI | |||||
Intake duration | < 12 wk | 6 | -0.535 (-0.782, -0.289) | 0.000 | 95.1% (0.000) |
= 12 wk | 2 | -0.220 (-0.920, 0.479) | 0.537 | 98.1% (0.000) | |
Dose per day | Low-dosage (< 100*108 CFU) | 4 | 0.024 (-0.351, 0.399) | 0.900 | 94.4% (0.000) |
High-dosage (≥ 100*108 CFU) | 4 | -0.829 (-1.125, -0.532) | 0.00 | 96.7% (0.000) | |
Combined with or without prebiotics | Probiotic alone | 6 | -0.481 (-0.730, -0.233) | 0.000 | 95.4% (0.000) |
Combined with prebiotics | 2 | -0.638 (-1.304, 0.027) | 0.060 | 97.9% (0.000) | |
Total cholesterol | |||||
Intake duration | < 12 wk | 6 | -0.225 (-0.443, -0.006) | 0.044 | 86.9% (0.000) |
= 12 wk | 4 | -0.665 (-0.906, -0.424) | 0.000 | 94.9% (0.000) | |
> 12 wk | 1 | -0.200 (-0.607,0.208) | 0.337 | ||
Dose per day | Low-dosage (< 100*108 CFU) | 9 | -0.496 (-0.664,0.328) | 0.000 | 93.4% (0.000) |
High-dosage (≥ 100*108 CFU) | 2 | 0.031 (-0.310, 0.371) | 0.860 | 0.00% (0.336) | |
Combined with or without prebiotics | Probiotic alone | 9 | -0.466 (-0.630, -0.303) | 0.000 | 92.7% (0.000) |
Combined with prebiotics | 2 | 0.004 (-0.377, 0.386) | 0.983 | 93.6% (0.000) | |
LDL | |||||
Intake duration | < 12 wk | 4 | -0.306 (-0.524, -0.088) | 0.006 | 81.2% (0.000) |
= 12 wk | 6 | -0.871 (-1.113, -0.628) | 0.000 | 94.1% (0.000) | |
> 12 wk | 1 | -0.250 (-0.658, 0.159) | 0.213 | ||
Dose per day | Low-dosage (< 100*108 CFU) | 9 | -0.558 (-0.725, -0.391) | 0.000 | 91.9% (0.000) |
High-dosage (≥ 100*108 CFU) | 2 | -0.333 (-0.685, 0.020) | 0.064 | 92.7% (0.000) | |
Combined with or without prebiotics | Probiotic alone | 9 | -0.609 (-0.774, -0.445) | 0.000 | 92.0% (0.000) |
Combined with prebiotics | 2 | -0.042 (-0.415, 0.331) | 0.826 | 84.8% (0.010) | |
HDL | |||||
Intake duration | < 12 wk | 4 | 0.557 (0.329, 0.784) | 0.000 | 94.0% (0.000) |
= 12 wk | 6 | 0.273 (0.027, 0.520) | 0.030 | 96.6% (0.000) | |
> 12 wk | 1 | -0.501 (-0.914, -0.087) | 0.018 | ||
Dose per day | Low-dosage (< 100*108 CFU) | 9 | 0.445 (0.272, 0.617) | 0.000 | 95.7% (0.000) |
High-dosage (≥ 100*108 CFU) | 2 | -0328 (-0.682, 0.025) | 0.069 | 93.7% (0.000) | |
Combined with or without prebiotics | Probiotic alone | 9 | 0.162 (-0.004, 0.329) | 0.056 | 95.4% (0.000) |
Combined with prebiotics | 2 | 1.158 (0.735, 1.581) | 0.000 | 96.2% (0.000) | |
Triglycerides | |||||
Intake duration | < 12 wk | 4 | -0.277 (-0.493, -0.061) | 0.000 | 0% (0.614) |
= 12 wk | 4 | -0.135 (-0.411, 0.140) | 0.336 | 93.0% (0.000) | |
Dose per day | Low-dosage (< 100*108 CFU) | 6 | -0.298 (-0.489, -0.107) | 0.770 | 97.4% (0.000) |
High-dosage (≥ 100*108 CFU) | 2 | 0.055 (-0.314, 0.424) | 0.069 | 0.0% (0.567) | |
Combined with or without prebiotics | Probiotic alone | 6 | -0.185 (-0.376, 0.006) | 0.058 | 88.3% (0.000) |
Combined with prebiotics | 2 | -0.368 (0.740, 0.004) | 0.052 | 39.4% (0.199) |
- Citation: Pongpirul K, Janchot K, Dai Y. Single strain probiotics for dyslipidemia, fatty liver, and obesity: A systematic review and meta-analysis. World J Meta-Anal 2019; 7(6): 323-338
- URL: https://www.wjgnet.com/2308-3840/full/v7/i6/323.htm
- DOI: https://dx.doi.org/10.13105/wjma.v7.i6.323